EyePoint Announces Participation at Upcoming Investor Conferences
EyePoint, Inc., a clinical-stage biopharmaceutical company focused on innovative therapeutics for serious retinal diseases, announced its participation in several upcoming investor conferences including Stifel, Jefferies, and Goldman Sachs. The company highlighted its lead product candidate, DURAVYU™, a sustained delivery treatment undergoing Phase…